IP Library Granted Patent US 9,683,007
Granted Patent B2
US 9,683,007 · App. 14/532,940 · Granted Jun 20, 2017

Methods for the purification of deoxycholic acid

Inventors: Robert M. Moriarty (Michiana Shores, IN); Achampeta Rathan Prasad (Hyderabad, IN); John Gregory Reid (Groton, MA); Roy A. Swaringen, Jr. (Durham, NC)
Assignee: Kythera Biopharmaceuticals, Inc.
C07J9/005A61K31/575C07J1/0011C07J5/0053C07J9/00C07J13/007C07J41/0061Y02P20/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,683,007
App. No.
14/532,940
Granted
Jun 20, 2017
Kind
B2
Abstract

Synthetic methods for preparing deoxycholic acid and intermediates thereof, high purity synthetic deoxycholic acid, compositions and methods of use are provided. Also, provided are processes for the synthesis of 12-keto or 12-α-hydroxysteroids from Δ-9,11-ene, 11-keto or 11-hydroxy-β-steroids. This inversion is also directed to novel compounds prepared during the synthesis. This invention is also directed to the synthesis of deoxycholic acid starting from hydrocortisone.

Claims (7)

1. A pharmaceutical composition comprising:

wherein the DCA has at least a purity of 96%, and

wherein the 12-β DCA is 0.4% or less of the total amount of the DCA and the 12-β DCA.

2. A method for reducing a subcutaneous fat deposit in a subject comprising administering locally to the subcutaneous fat deposit in the subject the composition of claim 1 .

3. A composition comprising:

wherein the 12-β DCA is 0.4% or less of the total amount of the DCA and the 12-β DCA.

4. A method for reducing a subcutaneous fat deposit in a subject comprising administering locally to the subcutaneous fat deposit in the subject the composition of claim 3 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2021
From: MORIARTY, ROBERT M.; PRASAD, ACHAMPETA RATHAN; REID, JOHN GREGORY; SWARINGEN, ROY A., JR.
To: KYTHERA BIOPHARMACEUTICALS, INC.
Reel/Frame 056904/0697 →
MERGER AND CHANGE OF NAME Recorded Nov 21, 2019
From: KYTHERA BIOPHARMACEUTICALS, LLC; ALLERGAN SALES, LLC
To: ALLERGAN SALES, LLC
Reel/Frame 051082/0736 →
CHANGE OF NAME Recorded Oct 10, 2019
From: KYTHERA BIOPHARMACEUTICALS, INC.
To: KYTHERA BIOPHARMACEUTICALS, LLC
Reel/Frame 050709/0885 →
Priority Claims (1)
GB 1008726 · May 25, 2010 · national
Continuity (6)
Continuation 13140421
Provisional Application 61288132 · Dec 18, 2009
Provisional Application 61302007 · Feb 5, 2010
Provisional Application 61303816 · Feb 12, 2010
Provisional Application 61348686 · May 26, 2010
Related Publication 20150141679A1 · May 21, 2015